Get started

Financials · ALLO

Allogene Therapeutics Inc. (ALLO) financials

For the twelve months ended Sep 30, 2026, Allogene Therapeutics Inc. reported $6.94M of revenue and -$174.46M of net income.

Revenue, TTM
$6.94M
Revenue growth, YoY
+269.5%
Net income, TTM
-$174.46M
Net margin
-2513.9%
Free cash flow, TTM
-$108.81M
EPS, diluted, TTM
-$0.63
Cash
$29.27M
P/S
52.77
Market cap
$366.2M
Annual revenue$2.60M
FY2019FY2025
Annual net income-$190.89M
FY2018FY2025
Annual free cash flow-$149.63M
FY2018FY2025

ALLO revenue and earnings growth

ALLO revenueQ3 2026$800.0K

Quarter YoY
+14.3%
QoQ
-82.8%
FY YoY
26x

ALLO revenue was $800.0K in fiscal Q3 2026 (ended Sep 30, 2026), up 14.3% from a year earlier and down 82.8% from the prior quarter. For the full fiscal 2025 it was $2.60M, up about 26-fold from fiscal 2024. It rose in 2 of the last 4 fiscal years.

ALLO net incomeQ3 2026-$50.37M

ALLO net income was -$50.37M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$41.40M a year earlier. For the full fiscal 2025 it was -$190.89M, compared with -$257.59M in fiscal 2024.

ALLO EPSQ3 2026-$0.15

ALLO diluted EPS was -$0.15 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$0.87, compared with -$1.32 in fiscal 2024.

ALLO free cash flowQ3 2026-$36.14M

ALLO free cash flow was -$36.14M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$29.93M a year earlier. For the full fiscal 2025 it was -$149.63M, compared with -$200.99M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue$2.60M$100.0K$95.0K$156.0K$114.09M$0$0-
Research and development$150.15M$192.30M$242.91M$256.39M$220.18M$192.99M$144.53M$151.86M
Selling, general and admin$56.78M$65.20M$71.67M$79.31M$74.11M$65.26M$57.47M$40.98M
Operating income-$209.31M-$273.20M-$327.74M-$335.54M-$180.19M-$258.24M-$202.01M-$192.84M
Interest expense$1.07M$181.0K$0--$0$0$3.36M
Pre-tax income-$190.89M-$257.15M-$327.26M--$257.00M-$250.22M-$184.93M-$211.62M
Income tax$0$443.0K$0$0$0$0-$331.0K-$117.0K
Net income-$190.89M-$257.59M-$327.26M-$340.41M-$182.05M-$316.38M-$184.59M-$211.50M
EPS, basic-$0.87-$1.32-$2.09-$2.38-$1.34-$2.63-$1.83-$7.31
EPS, diluted-$0.87-$1.32-$2.09-$2.38-$1.34-$2.63-$1.83-$7.31
Diluted shares220.6M194.8M156.9M143.1M135.8M120.4M101.1M28.9M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Cash and equivalents$51.69M$85.51M$93.45M$72.20M$173.31M$192.80M$179.43M$93.73M
Short-term investments----$283.99M$644.56M$355.41M$366.95M
Current assets$257.75M$303.39M$459.12M$528.82M$471.32M$845.13M$544.58M$467.98M
Total assets$415.90M$548.71M$642.84M$821.58M$1.05B$1.23B$717.80M$773.86M
Current liabilities$32.51M$35.52M$37.08M$53.73M$47.91M$94.32M$33.08M$29.46M
Total liabilities$123.36M$126.53M$130.60M$154.70M$125.63M$148.21M$88.78M$70.69M
Shareholders' equity$292.54M$422.18M$512.23M$666.88M$925.20M$1.01B$629.02M$703.16M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Operating cash flow-$149.25M-$200.30M-$237.73M-$220.52M-$184.81M-$115.09M-$137.35M-$44.65M
Capital expenditures$386.0K$694.0K$1.52M$5.19M$21.45M$65.96M$50.79M$3.23M
Free cash flow-$149.63M-$200.99M-$239.25M-$225.71M-$206.26M-$181.05M-$188.14M-$47.89M
Investing cash flow$95.56M$75.69M$163.29M$106.16M$163.66M-$505.12M$164.08M-$632.80M
Financing cash flow$30.16M$116.67M$95.69M$2.95M$11.96M$633.59M$58.96M$771.18M
Stock-based compensation$37.64M$51.74M$65.95M$83.60M$80.82M$65.26M$46.06M$18.57M
Depreciation and amortization$12.36M$13.64M$14.20M$14.30M$10.50M$7.40M$4.60M$1.00M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue growth, YoY2500.0%5.3%-39.1%-99.9%----
Operating margin-8050.6%-273199.0%-344986.3%-215087.2%-157.9%---
Net margin-7341.8%-257590.0%-344489.5%-218214.1%-159.6%---
Free cash flow margin-5755.1%-200994.0%-251841.1%-144685.9%-180.8%---
Return on equity-65.3%-61.0%-63.9%-51.0%-19.7%-31.2%-29.3%-30.1%
Return on assets-45.9%-46.9%-50.9%-41.4%-17.3%-25.8%-25.7%-27.3%
Current ratio7.938.5412.389.849.848.9616.4615.89

Source: XBRL data Allogene Therapeutics Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ALLO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ALLO$6.94M+269.5%-$174.46M-2513.9%$366.2M
AMGN$38.90B+8.2%$9.39B24.1%$251.65B
GILD$30.99B+6.5%-$3.86B-12.5%$210.01B
MRNA$2.52B+13.1%-$2.79B-110.5%$107.39B
ARGX$4.25B+88.6%$1.29B30.4%$59.72B
RVMD$0--$1.13B-$43.29B
BIIB$10.30B+2.3%$347.50M3.4%$37.67B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$17.51B

ALLO FAQ

8 questions
  • What is ALLO revenue?
    Allogene Therapeutics Inc. (ALLO) reported $6.94M of revenue for the twelve months ended Sep 30, 2026. That is up 269.5% from the year before. Revenue for fiscal 2025 was $2.60M.
  • Is ALLO profitable?
    No. Allogene Therapeutics Inc. reported a net loss of $174.46M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does ALLO have?
    Allogene Therapeutics Inc. reported $29.27M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ALLO revenue growing?
    Allogene Therapeutics Inc.'s revenue changed 26x in fiscal 2025, to $2.60M.
  • What is ALLO free cash flow?
    Allogene Therapeutics Inc. generated -$108.81M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$108.63M less capital expenditures.
  • What is ALLO earnings per share?
    Diluted earnings per share were -$0.63 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ALLO last report financial results?
    The latest statements here come from Allogene Therapeutics Inc.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.
  • Where does this ALLO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Allogene Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.